Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antipyrine as a model drug to study hepatic drug-metabolizing capacity.

Literature DB >> 3292639

Antipyrine as a model drug to study hepatic drug-metabolizing capacity.

H E Poulsen¹, S Loft.

Abstract

Entities: Chemical

Mesh：

Substances：
Antipyrine

Year: 1988 PMID： 3292639 DOI： 10.1016/s0168-8278(88)80057-6

Source DB: PubMed Journal: J Hepatol ISSN： 0168-8278 Impact factor: 25.083

Keyword Cloud
Cited

× No keyword cloud information.

15 in total

1. Simplified determination of antipyrine clearance by liquid chromatography of a microsample of saliva or plasma.

Authors: A el-Yazigi; D A Raines; H Ali; J Sieck; P Ernst; M Dossing
Journal: Pharm Res Date: 1991-02 Impact factor: 4.200

Review 2. Assessment of liver metabolic function. Clinical implications.

Authors: J Brockmöller; I Roots
Journal: Clin Pharmacokinet Date: 1994-09 Impact factor: 6.447

3. Lack of effect of zinc supplementation on antipyrine clearance in alcoholic liver disease.

Authors: K Grønbaek; H Friis; M Feldman; J Sonne; P B Andreasen
Journal: Eur J Clin Pharmacol Date: 1996 Impact factor: 2.953

4. Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance.

Authors: H Perrild; L Kayser; H E Poulsen; L Skovsted; B Jørgensen; J M Hansen
Journal: Br J Clin Pharmacol Date: 1989-11 Impact factor: 4.335

Review 5. Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors: Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal: Clin Pharmacokinet Date: 2014-12 Impact factor: 6.447

10. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.

Authors: L A Bauer; T O'Sullivan; W G Reiss; J R Horn; K Opheim; D E Strandness; R L Carithers
Journal: Br J Clin Pharmacol Date: 1994-04 Impact factor: 4.335

Antipyrine as a model drug to study hepatic drug-metabolizing capacity.

1. Simplified determination of antipyrine clearance by liquid chromatography of a microsample of saliva or plasma.

Review 2. Assessment of liver metabolic function. Clinical implications.

3. Lack of effect of zinc supplementation on antipyrine clearance in alcoholic liver disease.

4. Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance.

Review 5. Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

6. Antipyrine metabolism is not affected by terbinafine, a new antifungal agent.

7. Time-dependent disposition of beta-naphthoflavone in the rat.

8. Effect of chlormethiazole on hepatic monooxygenases activity in vivo.

9. Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism.

10. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.